drugset / Trial / NCT05027633
Immunotherapy With Chemotherapy and Chemoradiation for Advanced Squamous Cancer of Nasal Cavity / Paranasal Sinuses (I-NAPA)
NaSingle-groupOpen-labelTreatment
Summary
This is a single arm phase II study that will evaluate the combination of pembrolizumab, docetaxel, and cisplatin or carboplatin (PDC) as single treatment modality in patients with stage II-IVb (T2-4, any N, M0) squamous cell carcinoma of the nasal cavity/paranasal sinuses (PNS SCC).
Timeline
- Start
- 2021-11-02
- Primary completion
- 2028-03-30
- Completion
- 2028-03-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carboplatin | Small molecule | — | Intravenous |
| Subject | Cisplatin | Other / unclassified | — | Intravenous |
| Subject | Docetaxel | Small molecule | — | Intravenous |
| Subject | Pembrolizumab | Monoclonal antibody | — | Intravenous |